Yuta Katayama

3.0k total citations
96 papers, 1.0k citations indexed

About

Yuta Katayama is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Yuta Katayama has authored 96 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 25 papers in Public Health, Environmental and Occupational Health and 24 papers in Immunology. Recurrent topics in Yuta Katayama's work include Hematopoietic Stem Cell Transplantation (56 papers), Acute Myeloid Leukemia Research (37 papers) and Acute Lymphoblastic Leukemia research (24 papers). Yuta Katayama is often cited by papers focused on Hematopoietic Stem Cell Transplantation (56 papers), Acute Myeloid Leukemia Research (37 papers) and Acute Lymphoblastic Leukemia research (24 papers). Yuta Katayama collaborates with scholars based in Japan, United States and Greece. Yuta Katayama's co-authors include Keiichi I. Nakayama, Masaaki Nishiyama, Tsuyoshi Miyakawa, Hirotaka Shoji, Atsuki Kawamura, Yasuyuki Ohkawa, Tetsuya Sato, Mikita Suyama, Toru Takumi and Akiro Kimura and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yuta Katayama

86 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuta Katayama Japan	15	448	313	228	181	169	96	1.0k
Esther Choi United States	23	459 1.0×	562 1.8×	125 0.5×	266 1.5×	111 0.7×	38	1.9k
Mark D. Potter United States	16	611 1.4×	167 0.5×	367 1.6×	206 1.1×	110 0.7×	23	1.3k
Yo Niida Japan	21	453 1.0×	89 0.3×	334 1.5×	338 1.9×	155 0.9×	93	1.6k
Susan Moore United Kingdom	20	873 1.9×	317 1.0×	716 3.1×	204 1.1×	224 1.3×	30	2.0k
Dennis Burian United States	12	412 0.9×	164 0.5×	109 0.5×	108 0.6×	32 0.2×	24	871
Dominick Amato Canada	16	341 0.8×	275 0.9×	128 0.6×	131 0.7×	43 0.3×	42	1.1k
Gordana Raca United States	18	586 1.3×	138 0.4×	1.1k 4.6×	83 0.5×	88 0.5×	62	1.7k
Muhamed Baljević United States	12	556 1.2×	175 0.6×	109 0.5×	115 0.6×	112 0.7×	44	1.3k
Neal Farber United States	10	615 1.4×	117 0.4×	320 1.4×	228 1.3×	170 1.0×	14	1.5k
David C. Ward United States	15	805 1.8×	402 1.3×	267 1.2×	90 0.5×	51 0.3×	19	1.3k

Countries citing papers authored by Yuta Katayama

Since Specialization

Citations

This map shows the geographic impact of Yuta Katayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuta Katayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuta Katayama more than expected).

Fields of papers citing papers by Yuta Katayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuta Katayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuta Katayama. The network helps show where Yuta Katayama may publish in the future.

Co-authorship network of co-authors of Yuta Katayama

This figure shows the co-authorship network connecting the top 25 collaborators of Yuta Katayama. A scholar is included among the top collaborators of Yuta Katayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuta Katayama. Yuta Katayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goto, Tatsunori, Hiroshi Okamura, Takashi Ikeda, et al.. (2025). Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study. International Journal of Hematology. 122(1). 93–105. 1 indexed citations

Itonaga, Hidehiro, Yasushi Miyazaki, Jun Aoki, et al.. (2024). Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplantation. 59(8). 1107–1117. 2 indexed citations

Tamaki, Masaharu, Yu Akahoshi, Yoshihiro Inamoto, et al.. (2024). Associations between acute and chronic graft-versus-host disease. Blood Advances. 8(16). 4250–4261.

Jo, Tomoyasu, Yu Akahoshi, Tadakazu Kondo, et al.. (2024). First complete remission favours haploidentical haematopoietic stem cell transplantation with post‐transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia. British Journal of Haematology. 204(5). 1913–1919. 2 indexed citations

Kurosawa, Shuhei, Yoshimitsu Shimomura, Ken Ishiyama, et al.. (2024). Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study. Bone Marrow Transplantation. 59(6). 742–750. 1 indexed citations

Konuma, Takaaki, Kotaro Miyao, Hideki Nakasone, et al.. (2024). Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period. Cytotherapy. 26(8). 910–920. 2 indexed citations

Fuji, Shigeo, Ayumu Ito, Noriko Doki, et al.. (2024). Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation. Transplantation and Cellular Therapy. 30(5). 514.e1–514.e13.

Itonaga, Hidehiro, Yasushi Miyazaki, Kazunari Aoki, et al.. (2023). Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database. Annals of Hematology. 102(5). 1215–1227. 1 indexed citations

Ito, Yuri, Yoshihiro Inamoto, Koichi Miyamura, et al.. (2023). Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades. Transplantation and Cellular Therapy. 29(12). 768.e1–768.e10. 3 indexed citations

10.

Tamaki, Masaharu, Yu Akahoshi, Yosuke Okada, et al.. (2023). Unrelated female-to-male bone marrow transplantation would be preferred over cord blood transplantation in male patients. Cytotherapy. 25(11). 1220–1228. 1 indexed citations

11.

Jo, Tomoyasu, Yasuyuki Arai, Tadakazu Kondo, et al.. (2023). Prognostic impact of complex and/or monosomal karyotypes in post‐transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach. British Journal of Haematology. 202(2). 356–368. 1 indexed citations

12.

Konuma, Takaaki, Hidehiro Itonaga, Ken Ishiyama, et al.. (2023). Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?. Bone Marrow Transplantation. 58(8). 893–906. 2 indexed citations

13.

Yanagisawa, Ryu, Masaharu Tamaki, Reo Tanoshima, et al.. (2022). Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group. Hematological Oncology. 41(3). 535–545.

14.

Fujimoto, Ayumi, Tatsuhiko Anzai, Takahiro Fukuda, et al.. (2021). Impact of Event-Free Survival Status after Stem Cell Transplantation on Subsequent Survival in Lymphoma Patients. Transplantation and Cellular Therapy. 27(3). S62–S65.

15.

Yamasaki, Satoshi, Nobuharu Fujii, Yasushi Ishida, et al.. (2021). Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American Journal of Hematology. 97(2). 185–193. 2 indexed citations

16.

Arai, Yasuyuki, Shigeki Hirabayashi, Tadakazu Kondo, et al.. (2021). Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy‐refractory or relapsed disease prior to allogeneic stem cell transplantation. British Journal of Haematology. 194(2). 403–413. 2 indexed citations

17.

Kobayashi, Shinichi, Yoshinobu Kanda, Takaaki Konuma, et al.. (2021). Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplantation. 57(1). 43–50. 5 indexed citations

18.

Kurosawa, Shuhei, Shohei Mizuno, Yasuyuki Arai, et al.. (2021). Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer Journal. 11(9). 159–159. 3 indexed citations

19.

Yanada, Masamitsu, Takaaki Konuma, Satoshi Yamasaki, et al.. (2020). Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplantation. 56(5). 1126–1133. 26 indexed citations

20.

Kaito, Satoshi, Y. Nakajima, Konan Hara, et al.. (2020). Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Advances. 4(6). 1051–1061. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact